Background: CD4 + CD25 + regulatory T cells (Tregs), a heterogeneous population, were enrichment in tumor mass and played an important role in modulating anti-tumor immunity. Recently, we reported a Treg subset, CCR6
Introduction

CD4
+ CD25 + regulatory T cells (Treg), a subpopulation of CD4 + T cells constitutively expressing transcription factor forkhead box protein3 (Foxp3), consist 5-10% peripheral CD4 + T cells in normal human and mice [1] . CD4 +
CD25
+ Tregs effectively suppress the proliferation and activity of both CD4 + CD25 2 and CD8 + T cells in a contact-dependent manner through inhibition of interleukin 2 (IL-2) production [2] . Accumulating data have indicated that Tregs were enriched in tumor mass and potently inhibited the anti-tumor immunity mediated by CD4 + Th1 and CD8 + CTL [3, 4] . However, the exact mechanism of Tregs were enriched in tumor mass remains not fully understood.
Recently, some findings have indicated that there are distinct subsets of Tregs which play different roles in diverse animal models, mediating immune suppression or immune tolerance [5] [6] [7] [8] [9] . However, whether a distinct subset of Tregs is present in tumor environment and their role in mediating immunosuppression remains to be elucidated [10] . Previous study demonstrated a new subset of Tregs, which express CC chemokine receptor type 6 (CCR6), played an important role in the pathogenesis of experimental allergic encephalomyelitis (EAE) [11] . Kitamura et al further found that CCR6
+ regulatory T cells contributed to the pathogenesis of experimental colitis [12] . In the setting of tumors, Lamprecht et al reported that CCR6
+ Tregs might favor immune escape of Hodgkin/Reed-Sternberg (HRS) cells [13] . Our recent work further showed that CCR6 + subset of Treg cells were dominantly enriched in tumor mass and closely related to poor prognosis of breast cancer patients [14] . Combing these data suggested that CCR6
+ Tregs might play a critical role in immunosuppression of anti-tumor immunity. However, the underlying mechanism of the enrichment of this Treg subset in tumor mass remains to be elucidated, which might be helpful for the understanding of mechanisms of contribution of distinct Treg subsets to immunosuppression and ultimately aid the designing of therapy for treating tumor patients. To this end, in the present study, the distribution of CCR6
+
Tregs was evaluated in a murine breast cancer model. Our data showed that CCR6 + Tregs were dominantly enriched in the tumor mass during tumor progression. Notably, we provided evidence that the predominant proliferation of CCR6 + Tregs was crucial for their enrichment and suppressive effects in vivo. Finally, the possible role of tumor resident DCs in the proliferation of CCR6 + Tregs was studied.
Results
CCR6
+ Foxp3 + regulatory T cells were enriched in tumor mass during progression of breast tumor Our previous data found that CCR6
+
Foxp3
+ regulatory T cells were dominantly enriched in tumor mass and closely related to poor prognosis of breast cancer patients [14] , to further investigate the mechanism of the enrichment of this tumor-resident Treg subset, the frequency of CCR6 + Tregs in TILs during tumor progression was observed. As shown in fig. 1a (Fig. 1b) and displayed simlar response to CCL17 and CCL22 to CCR6 Tregs did (Fig S1) . In addition, the concentration of CCL17, CCL20 and CCL22 in supernatant also were determined (Fig S2) . (Fig. 2a, p To elucidate whether local prior proliferation of CCR6 + Tregs contributed to their accumulation in tumor mass, we treated 4T1 bearing mice with vinblastine (a cell cycle inhibitor) as described previously [16] . As expected, vinblastine treatment significantly reduced the in situ proliferation of CCR6 + Tregs (Fig. 2c , p,0.05) compared with control group. Importantly, the proportion of CCR6 + Tregs in tumor mass in vinblastine treated groups also decreased significantly compared with control group (Fig. 2d , p,0.05). In contrast, there was little effect of vinblastine treatment on the proportion of CCR6
2
Tregs in tumor mass. Subsequently, vinblastine treatment also significantly reduced the proportion of Tregs in tumor mass (Fig. 2e, p 
T cells than their CCR6
2 counterparts did [20] . Then, whether in situ prior expansion of CCR6 + Tregs might be responsible for their enrichment and subsequently suppressive effects in vivo was investigated. As shown in fig. 5a ,b, CCR6 + or CCR6 2 Tregs were sorted from TILs and pretreated with or without vinblastine. Then cells were transferred into 4T1 bearing syngeneic nude mice with 4T1 specific CD8
+ T cells at a ratio of 1:2 respectively. As shown in fig. 5a , vinblastine pre-treatment obviously decreased CCR6 + Treg frequency in tumor mass from 5.43% to 2.13% (p,0.05). Correspondingly, IFN-c production of CD8 + T cells in CCR6 + Tregs co-transferred mice was 2.89%, while it increased dramatically to 6.11% when the co-transferred CCR6 + Tregs were pre-treated with vinblastine (Fig. 5b, p,0.05) . Similar results were obtained on the proliferation, as well as expression of CD107a and Granzyme B, of CD8 + T cells (Fig. 5c,d , p,0.05). Finally, the size of tumor mass in CCR6
+ Tregs co-transferred mice was significantly elevated compared with that in CD8 +
T cells transferred group and CCR6
2 Tregs co-transferred group, while it decreased obviously in vinblastine pre-treated CCR6 + Tregs co-transferred group (Fig. 5e, p,0.05) .
In addition, vinblastine pretreatment also limitedly reduced the percentage of CCR6
2 Tregs in tumor mass (Fig. 5a , p.0.05) and led to slightly elevated IFN-c production and proliferation, as well as the expression of CD107a and Granzyme B, of CD8 + T cells (Fig. 5b,c,d, p.0.05) . Altogether, all our data suggested that in situ dominant proliferation capacity was critical for the enrichment and suppressive effect of CCR6 + Tregs in vivo.
Discussion
In the present study, we showed that CCR6 +
Tregs but not CCR6
2 Tregs were enriched in tumor mass during tumor progression in murine breast cancer model. And it was found that predominant in situ proliferation of CCR6 [14] . In this study, we extended our pervious finding by demonstrating that CCR6 + Tregs, but not CCR6
2 Tregs were enriched in tumor mass during progression of breast cancer. CCR6
+ Tregs displayed a phenotypic and functional characteristic of memory-effector T cells, expressing high level of CD44 and low level of CD62L, which is consistent with other work [11] .
Previous evidence suggested that chemokine family members, such as CCL17 and CCL22, direct the movement of Tregs in tumor mass [21, 22] . Recent evidence further indicated that conversion of CD4 +
CD25
2 T cells into Tregs, as well as local proliferation of Tregs also was contributed to local enrichment of Tregs [23, 24] . Notably, we extended others work by demonstrating that CCR6 + Tregs, but not CCR6 CD11c + DCs were found by our previously finding to be accumulated in tumor sites during tumor progression [25] . Here, we further found that tumor-resident DCs significantly triggered the proliferation of CCR6 + T cells in a TGF-b dependent manner. Similar work also reported immature DCs-induced TGF-bdependent Treg proliferation [26, 27] . Meanwhile, our data found that DLN derived DCs had little effect on the proliferation of CCR6 + Tregs suggesting that distinct DC subsets have heterogeneous effects on Tregs which awaits further research works.
To the discrepancies on the proliferation of CCR6
+
Tregs and CCR6
2 Tregs in vivo, we presumed that the prior proliferation of CCR6 + Tregs was dominantly dependent on two factors. On the one hand, memory T cells are more readily activated than naive cells, as evidenced by their ability to respond to lower doses of Ag, by their lesser dependence on co-stimulatory receptor-ligand interactions, and by their enhanced responses to stimulation with TCR antibody [28, 29] . Our present data showed that CCR6 Tregs in tumor mass might be partly attributed to their different sensitivity following interaction with intra-tumoral DCs. However, the exact mechanism remains to be elucidated in successive work.
In all, this research represents as the first report to elucidate the mechanism of the selective enrichment of CCR6 + Tregs but not CCR6
2 Tregs in tumor mass. And tumor-resident DC secreting TGF-b seems to be crucial for the in situ expansion and suppressive effect of CCR6 + Tregs in vivo. This study might throw a new insight on the understanding of orientation and function-sustaining mechanism of unique regulatory T cell subset in the setting of breast tumor and provide helpful thoughts for the designing of Treg-based immunotherapy for tumor in the future.
Materials and methods
Animals
Female Balb/c mice and Balb/c nude mice 5-6 weeks of age were purchased from the Center of Experimental Animal, Fudan University (Shanghai, China). All animals were housed in the pathogen free mouse colony at our institution and all animal experiments were performed according to the guidelines for the Care and Use of Laboratory Animals (Ministry of Health, PR China, 1998) and all the experimental procedure was approved by the ''the ethical guidelines of Shanghai Medical Laboratory Animal Care and Use Committee'' (permit number:2007013).
Cell lines
4T1 cell line, a Balb/c spontaneous metastatic mammary carcinoma, were cultured at 37uC under 5% CO 2 in completed RPMI 1640 (GIBICO, Grand land, NY, USA) medium containing 10% heat-inactivated fetal bovine serum and supplemented with 2 mM glutamine, 100 IU/ml penicillin, and 100 ug/ ml streptomycin sulfate.
Nude mice tumor model and co-transfer experiment
Syngeneic female nude mice were injected subcutaneously with 0.2 ml of a single-cell suspension containing 2610 5 4T1 adenocarcinoma cells in the right anterior mammary fat pad region. 7 days later, 4T1 specific CD8 + T cells were transferred with or without CCR6
+
Tregs and CCR6
2 Tregs at a ratio of 2:1 through tail vein respectively. 21 days later, the size of tumor mass in each group was obtained as previous described [3] . To obtain 4T1 specific CD8 + T cells, Balb/c mice were immunized with inactivated 4T1 tumor cells 3 times, with 1-week-interval. Then CD8 + T cells were sorted from splenocytes and re-stimulated with inactivated 4T1 tumor cells for 24 h in vitro.
Isolation of TILs
The lymphocytes were harvested from 4T1 tumors by a discontinuous density gradient method. Briefly, 4T1 tumors were removed aseptically and minced with scissors into 1-2 mm 3 pieces. The minced tumors were then stirred in 40 ml complete RPMI 1640 containing 40 mg collagenase, type IV(Sigma), 4 mg deoxyribonuclease (Sigma) and 100 U hyaluronidase (Sigma) for 3 h at room temperature. The tumor cell suspension was filtered through a nylon-mesh screen with pores of 50 mm to remove cell clumps, and the filtrate was then centrifuged (250 g, 10 min). The cell pellet was washed twice with serum-free RPMI 1640 and resuspended in complete RPMI 1640. A 4-ml aliquot of cell suspension of disaggregated tumor was placed on top of the gradient formed by overlapping a cushion of 100% Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ) with an equal volume of 75% Ficoll-Paque in RPMI 1640. Gradients (14 ml) were centrifuged at 800 g for 30 min at room temperature. The distinct band formed at the interface between 75% and 100% FicollPaque was collected and washed three times in fresh medium.
Flow cytometry
Flow cytometry was performed on a FACS Calibur (BD Biosciences) with CellQuest Pro software using directly conjugated mAbs against the following markers: CD3-FITC, CD4-PerCP, CD25-allophycocyanin, CCR6-PE with corresponding isotype-matched controls (either BD Biosciences or eBioscience Systems). Foxp3 staining was conducted using the mouse Regulatory T cell staining kit (eBioscience) and run according to the manufacturer's protocol. To determine the percentage of CCR6 + Tregs and CCR6
2
Tregs, lymphocytes were gated by plotting forward vs side scatter followed by gating on CD4 +
CD25
high T cells, and these cells were then analyzed for Foxp3 expression and CCR6 expression.
To determine the expression level of CD107a on CD8 + T cells, after staining of surface markers (CD8), cells were washed twice with PBS. Antibodies to CD107a and corresponding isotype controls were obtained from BD Biosciences. Cells were stained with antibody against CD107a (1:100) at 25uC for 20 min and washed before analysis.
Suppression assays
To test CCR6
+ Treg cells suppressive activity, 5610 4 CD4 + CD25 2 cells were treated with 2 mg/ml anti-CD3(eBioscience) and anti-CD28 (eBioscience) for 12 hrs as effector cells, then incubated with or without CCR6 + Tregs at a ratios of 2:1 for 72 hrs in complete medium containing RPMI 1640 (Sigma, St. Louis, MO) supplemented with 5% FCS.
[3 H ] thymidine (0.5 mCi/well) was added for the last 18 hours of culture. 
BrdU labeling
The 4T1 bearing Balb/c mice and syngeneic nude mice were treated with 2 mg BrdU(5-bromo-2-deoxyuridine; Sigma) i.p. every other day up to a cumulative dose of 8 mg BrdU as indicated. Eight hours after the last BrdU injection, TILs recovered from the tumor mass were analyzed by flow cytometry for their incorporation of BrdU. In brief, TILs were stained with antibodies for cell surface markers and fixed and permeabilized using Cytofix/Cytoperm and Perm/Wash buffer (BD Biosciences) according to the manufacturer's instructions. Cells were incubated at 24uC for 30 min in 0.15 M NaCl, 4.2 mM MgCl 2 , 10 mM HCl, pH 5 in the presence of 2 U DNase I (Invitrogen), followed by staining with aBrdU-FITC (eBioscience) for 30 min and were finally analyzed by FACS.
Design of artificial siRNAs and transfection
We designed the TGF-b targeting sequence (sense, 59-GAC-CAUCGACAU--GGAGCUG-39). The nonspecific control siRNA duplexes were purchased from Dhamacon with the same GC content as TGF-b siRNAs (52.4%, D001810-02). These siRNA gene doublestrands were ligated with pSilencer2.0 U6 RNAi Expression Vector (Ambion). Then, the vector with TGF-b-siRNA or control siRNA plasmids were transiently transfected into the CD11 + DC cells using Lipofectamine-2000 (Invitrogen) according to the manufacturer's instruction.
Chemotaxis assay
Chemotaxis assays were performed using 24-well Transwell chemotaxis plates (5-mm pore size; Corning Costar) as described previously [15] . Cell culture supernatants from 4T1 tumor cell lines or various concentrations of recombinant murine CCL17, CCL20, or CCL22 (100 ng/mL; R&D Systems, Minneapolis, MN) in RPMI 1640 medium were added to the lower chamber of the Transwell plates. CCR6
+
Tregs or CCR6
2 Tregs (1610 5 cells) were transferred into upper chambers. After 150 min at 37uC, chemotaxis was quantified by detecting the numbers of cells that migrated into the lower chamber. The chemotaxis index was calculated by dividing the numbers of cells migrated in response to test supernatants or recombinant human chemokines by the numbers of cells migrated in response to medium alone.
To obtain culture supernatant, 4T1 cell lines (0.5610 6 /ml) were cultured for 48 hrs. The culture supernatants then were collected and used in chemotaxis assays. For Ab-blocking assays, various concentrations of neutralizing anti-CCL22 (500 ng/mL), anti-CCL17(500 ng/mL), and anti-CCL20 (500 ng/mL) (R&D Systems) Abs were added to supernatants and incubated at 37uC for 30 min before performing chemotaxis assays.
Enzyme-linked immunosorbent assays
Tumor cell lines (0.5610 6 /ml) were cultured for 48 hrs. The culture supernatants were collected and performed using Quantikine Immunoassay kits specific for murine CCL17, CCL22 and CCL20, according to the manufacturer's instructions (all from R&D Systems). 
CFSE labeling
Cells were purified from 4T1 bearing mice by FACS sorting and labeled with 5-carboxy-fluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Leiden, The Netherlands) as previously described [3] . 2610
6 CFSE-labeled cells were intratumorally injected into 4T1 bearing syngeneic mice. 10 days later, single-cell suspensions of tumor infiltrating lymphocytes were prepared and the proliferation of cells were analyzed by FACS.
Statistical analyses
Statistical analyses of the data were performed with the aid of analysis programs in SPSS12.0 software. Statistical evaluation was performed using one way analysis of variance (ANOVA; p,0.05) or t test using the program PRISM 4.0 (GraphPad Software Inc., San Diego, CA, USA). Figure S1 The migration of CCR6 + Treg cells and CCR6
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2 Treg cells in response to CCL17/CCL22 and CCL20. The migration of CCR6
+
Tregs and CCR6
2 Tregs in response to CCL17/CCL22 (100 ng/ml) or CCL20 (100 ng/ml) were perfomed by transwell migration assays respectively as described in Material and Methods. One representative data of three independent experiments was shown. *p,0.05. (DOC) Figure S2 The supernatant concentration of CCL17, CCL20 and CCL22. 4T1 tumor cell lines (5610 5 /ml) were cultured for 48 hrs. The culture supernatants were collected and the concentration of CCL17, CCL20 and CCL22 were determined by ELISA assay and calculated. One representative data of three independent experiments was shown. (DOC) Tregs in response to supernatants were perfomed by transwell migration assays as described in Material and Methods. After preincubation for 30 minutes at 4uC with anti-CCL17, anti-CCL20 and anti-CCL22 mAbs (500 ng/mL), CCR6
+
Tregs and CCR6
2 Tregs migration were also tested by transwell migration assays respectively. One representative data of three independent experiments was shown. *p,0.05. 
